Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma: 5-year analysis of the EORTC-NCIC trial (2009)

Peer-Reviewed Study · Stupp R, Hegi ME, Mason WP, et al.; EORTC Brain Tumour and Radiation Oncology Groups; NCIC Clinical Trials Group · May 2009

Stupp R et al., 2009-05: Five-year final analysis of the same 573-patient trial. Five-year survival was 9.8% with temozolomide versus 1.9% with radiotherapy alone, while 89% and 97% of the two arms respectively had died within five years.

Overall survival was 27.2% (95% CI 22.2-32.5) at 2 years, 16.0% (12.0-20.6) at 3 years, 12.1% (8.5-16.4) at 4 years, and 9.8% (6.4-14.0) at 5 years with temozolomide, versus 10.9% (7.6-14.8), 4.4% (2.4-7.2), 3.0% (1.4-5.7), and 1.9% (0.6-4.4) with radiotherapy alone

p.459 (Summary, Findings)

Stupp R et al., 2009-05: Five-year final analysis of the same 573-patient trial. Five-year survival was 9.8% with temozolomide versus 1.9% with radiotherapy alone, while 89% and 97% of the two arms respectively had died within five years. FUNDING line (verbatim): 'EORTC, NCIC, Nelia and Amadeo Barletta Foundation, Schering-Plough.' Schering-Plough manufactured temozolomide. Comparator: radiotherapy alone. A five-fold relative increase in 5-year survivors, but roughly nine in ten patients still died within five years. Study type: randomized trial.